A phase 2b, double-blind, randomized, placebo-controlled, parallel group, dose ranging study of oral PF-06651600 and PF-06700841 as induction and chronic therapy in subjects with moderate to severe uncerative colitis

ENSAYO CLINICO COMERCIAL